YieldMax TSLA績效與分配目標25主動型ETF TEST 深 滬
等待開盤 06-10 09:30:00 美东时间
43.8744
-1.257
-2.79%
華盛通- 最 高43.8744
- 今 開43.31
- 成交量 1759股
- 最 低 42.61
- 昨 收 45.1319
- 總市值 219.37万
- 52周最高 52.2461
- 市盈率 靜 --
- 換手率 3.52%
- 52周最低 38.5425
- 委 比 0.00%
- 總股本 5.00万
- 歷史最高 52.2461
- 量 比 0.73
- 振 幅 2.80%
- 歷史最低 38.5425
- 每 手 1
- 風險率 2.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Element Materials Technology acquires mechanical testing lab MAR-TEST
Element Materials Technology acquires mechanical testing lab MAR-TEST Element Materials Technology acquired MAR-TEST, a Cincinnati-based mechanical testing laboratory, in a deal announced Feb. 1, 2012. The purchase expands Element’s testing services for aerospace and defense, power generation, and m
06-04 16:48
LIVE MARKETS-Nine days up: Nasdaq rolls on, but warning lights flicker
LIVE MARKETS-Nine days up: Nasdaq rolls on, but warning lights flicker Nasdaq 100 futures barely up, S&P 500, Dow futures modestly red May ADP National Employment 122k vs 118k estimate Euro STOXX 600 index off ~0.5% Dollar gains; US crude up >2%; gold dips; bitcoin off ~0.6% US 10-year Treasury yiel
06-03 21:03
LIVE MARKETS-Marvell, a fitting name for the latest AI darling
LIVE MARKETS-Marvell, a fitting name for the latest AI darling Adds blog post Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com . MARVELL, A FITTING NAME FOR THE LATEST AI DARLING Notw
06-03 14:03
BRIEF-Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer
BRIEF-Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer May 30 (Reuters) - Veracyte Inc VCYT.O : VERACYTE - ENZAMET TRIAL SHOWS DECIPHER PROSTATE TEST IDENTIFIES CHEMOTHERAPY BENEFIT IN METASTATIC PROSTATE CANCER Source text: ID:nB
05-30 20:14
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses May 30 (Reuters) - Grail Inc GRAL.O : GRAIL REPORTS FULL RESULTS FROM NHS-GALLERI TRIAL DEMONSTRATING SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES AT 2026 ASCO ANNUAL MEETIN
05-30 20:14
BRIEF-Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib
BRIEF-Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib May 30 (Reuters) - Cogent Biosciences Inc COGT.O : COGENT BIOSCIENCES ANNOUNCES DETAILED CLINICAL DATA FROM PEAK PHASE 3 TRIAL WITH BEZUCLASTINIB IN COMBINATION WITH SUN
05-30 20:03
TABLE-J. E. T. <6228.T>- 9-MTH group results
May 29 (Reuters)- J. E. T. Co., Ltd. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Sep 30, 2024 Sep 30, 2023 Dec 31, 2024 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sal
05-29 12:00
TABLE-J. E. T. <6228.T>-2025 group results
May 29 (Reuters)- J. E. T. Co., Ltd. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Dec 31, 2025 Dec 31, 2024 Dec 31, 2026 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FOR
05-29 12:00
GLOBAL MARKETS-Shares falter, oil gains as Gulf hostilities heat up
GLOBAL MARKETS-Shares falter, oil gains as Gulf hostilities heat up Nikkei flat, Europe and Nasdaq futures slip U.S. military strikes Iran base, Kuwait reports attacks Core PCE inflation data to test Fed rate outlook Adds reports of attack on Kuwait, updates prices By Wayne Cole SYDNEY, May 28 (Reut
05-28 11:14
RPT-ROI-US private credit contagion threat is small, but indirect risks remain: Deborah Cunningham
RPT-ROI-US private credit contagion threat is small, but indirect risks remain: Deborah Cunningham Repeats to additional subscribers without any changes. The views expressed here are those of the author, executive vice president and chief investment officer of Global Liquidity Markets at Federated H
05-26 20:00
